AI Article Synopsis
- MCAP (Megalencephaly-capillary malformation-polymicrogyria syndrome) is a rare neurological disorder caused by mutations in the PIK3CA gene, leading to abnormal brain growth, vascular issues, and body overgrowth.
- A clinical report details an infant diagnosed with MCAP, who showed signs of the disorder from prenatal imaging, which identified megalencephaly and a confirmed PIK3CA mutation postnatally, followed by early medical interventions.
- Despite these interventions, the patient faced ongoing challenges such as macrocrania, hydrocephalus, and neurodevelopmental delays, highlighting the importance of multidisciplinary care and monitoring to manage the complexities of the disorder and emphasizing potential future therapies for better outcomes.
Article Abstract
Background: Megalencephaly-capillary malformation-polymicrogyria syndrome (MCAP) is a rare neurological disorder characterized by abnormal brain size, vascular malformations, and body overgrowth. MCAP is caused by somatic mosaicism of PIK3CA, a crucial gene in regulation of cell growth and survival, and is one of the disorders in the PIK3CA-related overgrowth spectrum.
Methods: We present a unique clinical report of a male infant diagnosed with MCAP from prenatal stages to age 12 months. Prenatal imaging unveiled ventricular asymmetry, later confirmed postnatally as megalencephaly. Genetic analysis identified a PIK3CA mutation. The patient underwent early interventions, including ventriculoperitoneal shunt placement and posterior fossa decompression.
Results: Despite early interventions, the patient developed progressive macrocrania, hydrocephalus, and significant neurodevelopmental delay. Multidisciplinary management and continuous neuroimaging were crucial in addressing complications associated with the disorder.
Conclusions: This case underscores the critical need for multidisciplinary care and continual neuroimaging surveillance to effectively navigate the progressive complications associated with PIK3CA-related overgrowth spectrum. The diagnostic hurdles and management challenges intrinsic to the disorder's natural course are elucidated. Although current treatments manage symptoms, emerging therapies hold promise for improving patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pediatrneurol.2024.11.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in the Treatment of Congenital Infiltrating Lipomatosis of the Face: The Role of PIK3CA Mutations and Microvascular Reconstruction.
J Craniofac Surg
October 2024
Department of Oral Maxillofacial Surgery, Walter Reed National Military Medical Center.
Congenital infiltrating lipomatosis of the face is a rare aggressive-benign disorder characterized by progressive hemifacial overgrowth and complex, often asymmetrical, facial differences. Recently linked with the PIK3CA-Related Overgrowth Spectrum, it arises from mosaic mutations in the PIK3CA gene. Treatment, largely supportive and tailored to individual clinical presentations, requires a multidisciplinary approach.
View Article and Find Full Text PDFPIK3CA-Related Overgrowth Spectrum: Exploring Brain Growth From Fetal to Infant.
Pediatr Neurol
November 2024
Department of Neonatology, Unidade Local de Saúde de Vila Nova de Gaia, Vila Nova de Gaia, Portugal.
Article Synopsis
- MCAP (Megalencephaly-capillary malformation-polymicrogyria syndrome) is a rare neurological disorder caused by mutations in the PIK3CA gene, leading to abnormal brain growth, vascular issues, and body overgrowth.
- A clinical report details an infant diagnosed with MCAP, who showed signs of the disorder from prenatal imaging, which identified megalencephaly and a confirmed PIK3CA mutation postnatally, followed by early medical interventions.
- Despite these interventions, the patient faced ongoing challenges such as macrocrania, hydrocephalus, and neurodevelopmental delays, highlighting the importance of multidisciplinary care and monitoring to manage the complexities of the disorder and emphasizing potential future therapies for better outcomes.
An immortalized adipose-derived stem cells line from the -related overgrowth spectrum: Unveiling novel therapeutic targets.
Biochem Biophys Rep
December 2024
Department of Plastic & Reconstructive Surgery, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
PIK3CA-related overgrowth spectrum (PROS) encompasses several rare conditions that lead to overgrowth of various body parts resulting from activating variants in . The absence of ideal cell models significantly impedes progress in PROS research. In this study, we focused on facial infiltrating lipomatosis (FIL) (A disorder within PROS) and aimed to establish and characterize an immortalized PROS cell line.
View Article and Find Full Text PDFPost-Abortem Detection of a Pathogenic Somatic PIK3CA-Variant in an Abdominal Lymphangioma That Is Not Present in Cultured Amniotic Fluid Cells.
Prenat Diagn
December 2024
Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Defining the transcriptome of PIK3CA-altered cells in a human capillary malformation using single cell long-read sequencing.
Sci Rep
October 2024
The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
PIK3CA-related overgrowth spectrum (PROS) disorders are caused by somatic mosaic variants that result in constitutive activation of the phosphatidylinositol-3-kinase/AKT/mTOR pathway. Promising responses to molecularly targeted therapy have been reported, although identification of an appropriate agent can be hampered by the mosaic nature and corresponding low variant allele frequency of the causal variant. Moreover, our understanding of the molecular consequences of these variants-for example how they affect gene expression profiles-remains limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!